MDxHealth SA is a commercial-stage precision diagnostics company, which engages in the development and commercialization of molecular diagnostic products for personalized cancer treatment. It operates through the following geographical segments: United States of America, Europe and Rest of the World. The firm offers ConfirmMDx, SelectMDx, AssureMDx, InformMDx, SelectMDx, and MonitorMDx. The company was founded by Herman Spolders and Philip S. Devine on January 10, 2003 and is headquartered in Herstal, Belgium.
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Mdxhealth and the University of Oxford have launched the GPS-ProtecT study to validate the Genomic Prostate Score test in predicting prostate cancer progression among patients on active surveillance. - The validation will leverage samples and data from the ProtecT trial, the world's largest randomized clinical trial of treatment effectiveness in localized prostate cancer, following over 1,500 men for more than two decades. - The study aims to establish GPS as the first genomic classifier supported by randomized clinical trial evidence in an active surveillance cohort, potentially redefining risk evaluation and personalized care for prostate cancer patients. - Previous 15-year ProtecT data showed low prostate cancer-specific mortality rates across all treatment groups: 3.1% for active monitoring, 2.2% for prostatectomy, and 2.9% for radiotherapy.
- ANGLE plc announces strategic rebrand to CelLBxHealth plc, reflecting sharpened focus on circulating tumor cell intelligence and liquid biopsy diagnostics. - Dr. Jan Groen transitions from Non-Executive Chairman to Executive Chairman, bringing 25 years of oncology diagnostics commercialization experience including successful turnaround of MDxHealth. - Company maintains cash runway through Q1 2026 while pursuing cost control measures and accelerated commercial partnerships in proteomics and genomics markets. - Strategic pivot emphasizes maximizing proprietary Parsortix platform potential by integrating existing proteomics and genomic assays with circulating tumor DNA insights.
- MDxHealth has completed the acquisition of Bio-Techne's ExoDx Prostate (EPI) test platform for $15 million, structured as $5 million in stock at closing and $2.5 million annually over four years. - The ExoDx Prostate test is a CLIA-certified, non-invasive urine-based diagnostic that uses exosome RNA analysis to detect clinically significant prostate cancer with greater accuracy than traditional PSA tests. - The acquisition is expected to contribute over $20 million in revenue by 2026 and accelerate MDxHealth's revenue growth to 30%, while being accretive to adjusted EBITDA starting in Q4 2025. - This strategic move positions MDxHealth to capitalize on the rapidly growing $10.5 billion liquid biopsy market, which is projected to grow at a 20% CAGR through 2033.
